Capital International Investors Gilead Sciences, Inc. Transaction History

Capital International Investors

$504 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $282 Million - $321 Million	-3,646,943 Reduced 99.81%	6,864 $569,000
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $58.1 Million - $83.4 Million	-932,078 Reduced 20.32%	3,653,807 $314 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $779,021 - $889,842	13,084 Added 0.29%	4,585,885 $283 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $74.2 Million - $83.6 Million	-1,285,963 Reduced 21.95%	4,572,801 $283 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $1.76 Billion - $2.21 Billion	-30,413,697 Reduced 83.85%	5,858,764 $348 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $206 Million - $234 Million	-3,177,699 Reduced 8.05%	36,272,461 $2.63 Billion
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $891,680 - $962,024	13,173 Added 0.03%	39,450,160 $2.76 Billion
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $37.7 Million - $41.1 Million	-593,224 Reduced 1.48%	39,436,987 $2.72 Billion
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $391 Million - $446 Million	-6,518,785 Reduced 14.0%	40,030,211 $2.59 Billion
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $112 Million - $128 Million	-1,984,981 Reduced 4.09%	46,548,996 $2.71 Billion
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $535 Million - $672 Million	-8,609,170 Reduced 15.07%	48,533,977 $3.07 Billion
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $56 Million - $65 Million	773,490 Added 1.37%	57,143,147 $4.4 Billion
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $2.72 Billion - $3.49 Billion	43,464,551 Added 336.8%	56,369,657 $4.21 Billion
Q4 2019 Feb 18, 2020	BUY	$61.62 - $67.78 $35.5 Million - $39 Million	575,721 Added 4.67%	12,905,106 $839 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $139 Million - $154 Million	2,228,763 Added 22.07%	12,329,385 $781 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $127 Million - $142 Million	2,049,862 Added 25.46%	10,100,622 $682 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $357 Million - $400 Million	-5,708,885 Reduced 41.49%	8,050,760 $523 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $496,609 - $648,037	8,203 Added 0.06%	13,759,645 $861 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $78.1 Million - $86.5 Million	-1,095,836 Reduced 7.38%	13,751,442 $1.06 Billion
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $463,891 - $541,112	7,150 Added 0.05%	14,847,278 $1.05 Billion
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $71.7 Million - $87.4 Million	983,931 Added 7.1%	14,840,128 $1.12 Billion
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $188 Million - $220 Million	2,639,182 Added 23.53%	13,856,197 $993 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $809 Million - $959 Million	11,217,015	11,217,015 $909 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.

Account